Clinical trials: Drug Distribution
Red Blood Cell Health, Biological Aging
Effect of Pentadecanoic Acid Supplementation on Red Blood Cell Health and Biological Aging in Healthy Older Adults
This Phase II randomized, double-blind, placebo-controlled, parallel-group study will evaluate the effects of pentadecanoic acid (C15:0) supplementation on red blood cell (RBC) health and predicted biological age in healthy…
- Conditions
- Red Blood Cell Health, Biological Aging, Healthy Aging
- Trial name
- NCT07812792
- Testing
- Pentadecanoic Acid
- Where
- Canada
- Volunteers
- 93 people, healthy volunteers welcome
- Sponsor
- ReCellience15, Inc
Cystic Fibrosis, Non-Cystic Fibrosis Bronchiectasis
A Clinical Study to Investigate Safety, Tolerability and Distribution of CHF 6333 After One or After Repeated Inhalation in Patients With Cystic Fibrosis (CF) and in Patients With Non Cystic Fibrosis (NCFB) Bronchiectasis
CHF 6333 is a medicinal product on development for the treatment of cystic fibrosis and non-CF bronchiectasis and undergoing clinical testing. It has not yet been approved by the authorities for the treatment of these diseases.
- Trial name
- NCT04010799
- Testing
- CHF 6333
- Where
- Germany
- Volunteers
- 68 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
KOA
A Study of [89Zr]-Oxine-NCR100 Injection for the Cellular Distribution
This clinical study is to evaluate the biodistribution of [89Zr]-Oxine-NCR100 injection in subjects with knee osteoarthritis after local injection and the kinetic behavior characteristics of zirconium-labeled cells at the…
- Trial name
- Distribution (NCT07139431)
- Testing
- NCR100
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Nuwacell Biotechnologies Co., Ltd.
Worsening Chronic Heart Failure, Chronic Kidney Disease
A Study to Learn How BAY94-8862 Moves Into, Through and Out of the Body, How Safe it is and How it Affects the Body in Adult Participants With Reduced Kidney Function and in Healthy Participants With Similar Age, Weight and Gender Distribution
Researchers are looking for a better way to treat people who have worsening of chronic heart failure, a long-term condition where the heart does not pump blood as well as it should.
- Trial name
- NCT04908436
- Testing
- Finerenone (BAY94-8862)
- Where
- Germany
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Bayer
Recurrent Glioblastoma Multiforme
Safety & Radiation Distribution Study of Cotara® in Patients With Recurrent Glioblastoma Multiforme
RATIONALE: Cotara® is an experimental new treatment that links a radioactive isotope (iodine 131) to a targeted monoclonal antibody.
- Trial name
- NCT00509301
- Testing
- 131-I-chTNT-1/B MAB
- Where
- 4 sites in United States
- Volunteers
- 12 people
- Sponsor
- Peregrine Pharmaceuticals
Healthy Volunteers
Absorption, Distribution, Metabolism and Excretion (ADME) Study With Single Oral Administration of [14C] NKTR-118
Study to Assess the Absorption, Metabolism and Excretion of [14C] NKTR-118 after a Single-Dose Oral Administration.
- Trial name
- NCT01348724
- Testing
- [14C] NKTR-118
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Schizophrenia
Bioequivalence Fasting Study in Patients
To compare and evaluate the oral bioavailability of Asenapine Sublingual Tablets, 10 mg manufactured by AMNEAL PHARMACEUTICALS, USA with SAPHRIS® (asenapine) sublingual tablets, 10 mg.
- Trial name
- NCT02072954
- Testing
- Asenapine Sublingual Tablets 10 mg
- Where
- 2 sites in India
- Volunteers
- 48 people
- Sponsor
- Amneal Pharmaceuticals, LLC
Body Fat Distribution, Cellulitis
Effect of Vibro-oscillatory Therapy for Improvement of Body Contour and Appearance of Cellulite.
OBJECTIVE: To evaluate the efficacy of vibro-oscillatory therapy through an electromedical equipment in improving body contour and appearance of cellulite.
- Trial name
- NCT03312946
- Testing
- Modellata
- Where
- Brazil
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Indústria Brasileira Equipamentos Médicos - IBRAMED
Healthy
A Study to Investigate the Absorption, Distribution, Metabolism, and Excretion of 14C-JNJ-42847922 After a Single Oral Dose of 40 mg in Healthy Subjects
The objective of this study is to evaluate the absorption, distribution, metabolism, and excretion (ADME) of 14C-JNJ-42847922 in healthy subjects after a single oral dose of 40 milligram (mg) 14C-JNJ-42847922 containing maximally…
- Trial name
- NCT03025022
- Testing
- 14C-JNJ-42847922 40 mg
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Healthy
A Study of the Absorption, Distribution, Metabolism and Excretion of LY3039478 in Healthy Participants
This type of study is called a radiolabeled study. For this study, LY3039478 (study drug) has been specially prepared to contain radiolabeled carbon [¹⁴C]. [¹⁴C] is a naturally occurring radioactive form of the element carbon.
- Trial name
- NCT02917733
- Testing
- LY3039478
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy Volunteer
A Study to Look at How a Single Oral Dose of Carbon-14-Labelled [14C] BIIB091 Moves Through and is Processed by the Body in Healthy Male Participants
The main goal of this study is to learn how [14C]-BIIB091 moves through and is processed by the body and to look at how much of BIIB091's metabolites (what is produced when BIIB091 is broken down by the body) appears in the…
- Trial name
- Mass Balance (NCT06311786)
- Testing
- [14C]-BIIB091
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Biogen
Alzheimer's Disease
Positron Emission Tomography (PET) Study With [18F]AZD4694 and [11C]AZD2184, Candidate PET Ligands for Aβ Amyloid
The study is carried out in order to investigate if [18F]AZD4694, compared to [11C]AZD2184, is a suitable PET ligand for in vivo imaging of Aβ amyloid depositions in the human brain.
- Trial name
- PET (NCT00838877)
- Testing
- radioligand [18F]AZD4694, radioligand [11C]AZD2184
- Where
- 2 sites in Sweden
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy
A Study in Healthy Men to Test How BI 1569912 is Processed in the Body
The main objectives of this trial are: To investigate basic pharmacokinetics of BI 1569912 and total radioactivity, including mass balance, excretion pathways and metabolism following oral administration of BI 1569912 (C-14) to…
- Trial name
- NCT06520553
- Testing
- BI 1569912 (C-14), BI 1569912 (C-13)
- Where
- Netherlands
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Pneumococcal Diseases
Serotype Distribution of Streptococcus Pneumoniae That Causes Invasive Diseases at Children and Adults in Turkey
The aim of this study is to specify the serotype distribution of Streptococcus pneumoniae that causes invasive diseases at children and adults in Turkey.
- Trial name
- NCT01810861
- Testing
- There is no intervention in this study
- Where
- 32 sites in Turkey (Türkiye)
- Volunteers
- 922 people
- Sponsor
- Pfizer
Healthy
A Study of the Hedgehog Pathway Inhibitor GDC-0449 in Healthy Female Subjects of Non-Childbearing Potential
This is an open-label, Phase I, single-center, single-dose administration study to determine the absolute bioavailability, clearance, and volume of distribution of GDC-0449 (Part A) and to determine the routes of excretion and…
- Trial name
- NCT00991718
- Testing
- GDC-0449 oral capsules (non-labeled), GDC-0449 IV injection (labeled), CDC-0449 oral suspension (labeled)
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Genentech, Inc.
Healthy, Psoriasis
Distribution of Secukinumab (AIN457) Into Dermal Interstitial Fluid After a Single Subcutaneous Administration of 300 mg
The proposed exploratory study aims to understand the in vivo skin distribution properties of subcutaneously (s.c.) administered AIN457 in psoriatic and healthy skin using open flow microperfusion (OFM).
- Trial name
- OFM ISF (NCT01539213)
- Testing
- secukinumab (AIN457)
- Where
- Austria
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Obstetric Labour, Premature, Premature Labor
Absorption, Distribution, Metabolism And Excretion Study For GSK221149A
This is a phase one study investigating the absorption, distribution, metabolism and excretion of GSK221149A in six healthy women of non-child bearing potential.
- Trial name
- NCT00457925
- Testing
- GSK221149A
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy
A Study Testing A Radioactive Compound Given Through A Vein With And Without The Non-Radioactive Compound, Given By Mouth, To Characterize Tissue Distribution Using Positron Emission Tomography Scanning
In this study, radioactive PF-06427878 will be administered, through a vein, alone and with 2 different oral doses of non-radioactive PF-06427878 to healthy, adult, male subjects.
- Trial name
- NCT02410525
- Testing
- [11C]PF-06427878, PF-06427878 10 mg, PF-06427878 600 mg
- Where
- 3 sites in United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Pfizer
Advanced Solid Tumors
A Single Center Study to Characterize the Absorption, Distribution, Metabolism and Excretion (ADME) of ASA404 After a Single Infusion in Patients With Solid Tumors
This study is designed to characterize the absorption, distribution, metabolism and excretion (ADME) of ASA404 following a single intravenous administration of 3000 mg (approximately 1800 mg/m2) ASA404 containing 60 µCi of 14C…
- Trial name
- NCT01299701
- Testing
- ASA404
- Where
- New Zealand
- Volunteers
- 7 people
- Sponsor
- Novartis Pharmaceuticals
Healthy
Study in Healthy Males to Assess Distribution, Metabolism, and Excretion of Radio-labelled AZD9742 Administered as a 2-hour Infusion
The purpose of this study is to assess distribution, metabolism, and excretion of radio-labelled AZD9742 administered as a 2-hour infusion to healthy male volunteers.
- Trial name
- NCT01275781
- Testing
- [14C]-AZD9742
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- AstraZeneca